biological response modifier; immune factor; immunomodulator; biomodulator
Jump to navigation
Jump to search
Introduction
Biologically active substances that affect the immune system.
The role may be stimulatory or inhibitory
Monitor
- evaluate vaccination status prior to administration of a biological response modifier
- administer recommended vaccinations[2]
Adverse effects
- not associated with increased risk of malignancy in patients with rheumatoid arthritis
More general terms
More specific terms
- adjuvant
- antineoplastic immunomodulator
- blinatumomab (Blincyto)
- checkpoint inhibitor
- dupilumab (Dupixent)
- ecallantide (Kalbitor)
- GRO-beta(5-73) (Garnocestim)
- immunosuppressive agent
- insulin-response enhancer
- interferon [IFN]-alfa 2a (Roferon-A)
- interferon [IFN]-alfa 2b (Intron A)
- interferon [IFN]-beta 1A (Avonex)
- interferon [IFN]-beta 1B (betaseron, Extavia)
- interferon-gamma 1B
- leniolisib (Joenja)
- mepolizumab (Nucala)
- oprelvekin [IL-11] (Neumega)
- pharmaceutical interferon
- Pharmalgen
- secukinumab (Cosentyx)
- sipuleucel-T (Provenge)
- sublingual allergen extract
- tebentafusp-tebn (Kimmtrak)
- thymosin
- topical immunomodulator (TIM)
- TP5 (Timunox, Sintomodulina, Mepentil)
References
- ↑ Lopez-Olivo MA et al Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-analysis JAMA. 2012;308(9):898-908 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22948700 <Internet> http://jama.jamanetwork.com/article.aspx?articleid=1356358
- ↑ 2.0 2.1 Ferreira I and Isenberg D. Vaccines and biologics. Ann Rheum Dis 2014 Aug; 73:1446 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24845388 <Internet> http://ard.bmj.com/content/73/8/1446
- ↑ NLM MeSH Browser http://www.nlm.nih.gov/mesh/meshhome.html